
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
XW Laboratories Inc. | XW10172 | Narcolepsy | Phase I trials initiated |
Cadent Therapeutics | CAD-1883 | Neurological (Essential Tremor) and psychiatric disease (Spinocerebellar ataxia) | Phase I trials initiated |
Arrowhead Pharmaceuticals, Inc. | ARO-AAT | Alpha-1 liver disease | Phase I trials initiated |
Voyager Therapeutics | VY-AADC | Advanced Parkinson’s disease | Phase Ib trials initiated |
Protalix Biotherapeutics, Inc. | OPRX-106 | Ulcerative colitis | Phase II trials initiated enrolling 24 subjects |
Merrimack Pharmaceuticals, Inc. | MM-121 | Lung cancer | Phase II trials initiated expanding from 80 to 100 subjects |
Biogen | SPINRAZA (nusinersen) | Spinal muscular atrophy (SMA) | Phase II trials initiated enrolling 25 pre-symptomatic infants six weeks old or younger |
MyoKardia | Mavacamten | Hypertrophic cardiomyopathy (HCM) | Phase II trials initiated |
AM-Pharma | recombinant human Alkaline Phosphatase (recAP) | Acute Kidney Injury (AKI) | Phase II trials initiated enrolling 301 subjects with sepsis |
Eleven Biotherapeutics, Inc. | Vicinium | Non-muscle invasive bladder cancer (NMIBC) previously treated with bacillus Calmette-Guérin (BCG) | Phase III trials initiated |
AbbVie | Elagolix | Uterine fibroids | Phase III trials initiated |
Merck | KEYTRUDA (pembrolizumab) | Advanced cervical cancer with disease progression on or after chemotherapy | Priority Review granted by the FDA |
Cerapedics, Inc. | P-15L | Transforaminal lumbar interbody fusion (TLIF) surgery for degenerative disk disease | IDE Approval granted by the FDA |
Proteostasis Therapeutics | PTI-428 | Cystic fibrosis | Breakthrough Designation granted by the FDA |
Upcoming Events
-
05Dec
-
14Apr